The latest price target for Arbutus Biopharma (NASDAQ:ABUS) was reported by Chardan Capital on November 20, 2024. The analyst firm set a price target for $5.00 expecting ABUS to rise to within 12 months (a possible 43.06% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for Arbutus Biopharma (NASDAQ:ABUS) was provided by Chardan Capital, and Arbutus Biopharma maintained their buy rating.

The last upgrade for Arbutus Biopharma Corp happened on February 2, 2022 when Jefferies raised their price target to $5. Jefferies previously had a hold for Arbutus Biopharma Corp.

There is no last downgrade for Arbutus Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a maintained with a price target of $4.50 to $5.00. The current price Arbutus Biopharma (ABUS) is trading at is $3.50, which is out of the analyst’s predicted range.